CORT
CORCEPT THERAPEUTICS INC
$72.62
-3.03%
$8.0B
No data for this timeframe.
Vol
Market Cap$8.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders9 funds
Inst. Value$735.8M
Inst. Activity2 buys / 1 sells
Insider Activity1B / 11S
Insider Net $-$13.6M
Reddit Sentiment50° Neutral
SEC Reports12
Recent Activity
Jun 4, 2026
SEC
Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a total of $6.91M in ope
CLUSTER — Impact 3/10
Jun 3, 2026
SEC
Four CORT insiders — including the CEO, CFO, and two senior executives — sold a total of $5.50M in open-market shares wi
CLUSTER — Impact 3/10
Jun 3, 2026
SEC
Four Corcept Therapeutics insiders, including the CEO, CFO, and two other senior executives, sold a total of $5.50M in o
CLUSTER — Impact 5/10
Jun 2, 2026
Insider
Guyer William sold 20,000 shares
Chief Development Officer @ $0.00 ($0.00)
Jun 2, 2026
Insider
Guyer William sold 20,000 shares
Chief Development Officer @ $70.60 ($1.4M)
Jun 2, 2026
Insider
Guyer William sold 20,000 shares
Chief Development Officer @ $21.65 ($433.0K)
Inst.
MORGAN STANLEY — ADD
1,592,059 shares ($55.4M)
Inst.
NORGES BANK — NEW
695,766 shares ($24.2M)
Price Targets
$88.00
+21.2% upside
Strong Buy
Current $72.62
Low $50.00
Median $88.00
High $135.00
5 analysts
$50.00
$135.00
Analyst Ratings
2Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 13, 2026 | UBS | UPGRADE | Neutral → Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 1, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.04 ▼ -29.5% | $0.02 — $0.06 | -87% YoY | 3 |
| Next Q | $0.25 ▲ +56.4% | $0.14 — $0.34 | 58% YoY | 3 |
| Current FY | $0.49 ▲ +20.1% | $0.17 — $0.80 | -41% YoY | 4 |
| Next FY | $2.50 ▲ +55.2% | $0.32 — $5.38 | 412% YoY | 4 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a total of $6.91M in ope
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Four CORT insiders — including the CEO, CFO, and two senior executives — sold a total of $5.50M in open-market shares wi
Jun 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $330.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $200.4M | — |
| FMR LLC | $84.0M | ADD |
| MORGAN STANLEY | $55.4M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $37.0M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Guyer William | M | $0.00 |
| Jun 2, 2026 | Guyer William | SELL | $1.4M |
| Jun 2, 2026 | Guyer William | M | $433.0K |
| Jun 2, 2026 | Lyon Joseph | F | $18.9K |
| Jun 2, 2026 | Maduck Sean | F | $31.8K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $735.8M total value (21,144,327 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, FMR. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,494,822 | $330.4M | 44.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 5,758,528 | $200.4M | 27.2% | — |
| 3 | FMR LLC | 2,414,640 | $84.0M | 11.4% | ADD +62.3% |
| 4 | MORGAN STANLEY | 1,592,059 | $55.4M | 7.5% | ADD +34.1% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,062,101 | $37.0M | 5.0% | ADD +31.4% |
| 6 | NORGES BANK | 695,766 | $24.2M | 3.3% | NEW |
| 7 | BANK OF AMERICA CORP /DE/ | 83,658 | $2.9M | 0.4% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 27,959 | $973.0K | 0.1% | TRIM -33.6% |
| 9 | WELLS FARGO & COMPANY/MN | 14,794 | $514.8K | 0.1% | NEAR_EXIT -78.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 1,186,978 | 1,592,059 | +34.1% | $55.4M | 2025-Q4 |
| NORGES BANK | NEW | — | 695,766 | — | $24.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 42,126 | 27,959 | -33.6% | $973.0K | 2025-Q4 |
| FMR LLC | ADD | 1,356,948 | 2,201,938 | +62.3% | $183.0M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 1,614,093 | 1,186,978 | -26.5% | $98.6M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 814,455 | 1,070,281 | +31.4% | $89.0M | 2025-Q3 |
| UBS Group AG | DOUBLED | 107,040 | 549,938 | +413.8% | $45.7M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 60,844 | 42,126 | -30.8% | $3.5M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 55,043 | 12,105 | -78.0% | $1.0M | 2025-Q3 |
| NORGES BANK | EXIT | 981,577 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 981,577 | — | $72.0M | 2025-Q2 |
| UBS Group AG | TRIM | 372,653 | 107,040 | -71.3% | $7.9M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 180,149 | 60,844 | -66.2% | $4.5M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 110,563 | 55,043 | -50.2% | $4.0M | 2025-Q2 |
| UBS Group AG | ADD | 250,162 | 372,653 | +49.0% | $42.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 264,721 | 334,763 | +26.5% | $38.2M | 2025-Q1 |
| NORGES BANK | EXIT | 834,591 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | TRIM | 1,259,978 | 834,591 | -33.8% | $42.1M | 2024-Q4 |
| UBS Group AG | ADD | 178,196 | 250,162 | +40.4% | $12.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 44,070 | 90,137 | +104.5% | $4.5M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,026,487 | — | $47.5M | 2024-Q3 |
13 unique insiders with 12 transactions. Net insider value: -$13.6M ($2.5M bought, $16.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Guyer William | Chief Development Officer | M | 20,000 | $0.00 | $0.00 |
| Jun 2, 2026 | Guyer William | Chief Development Officer | SELL | 20,000 | $70.60 | $1.4M |
| Jun 2, 2026 | Guyer William | Chief Development Officer | M | 20,000 | $21.65 | $433.0K |
| Jun 2, 2026 | Lyon Joseph Douglas | See Remarks | F | 269 | $70.44 | $18.9K |
| Jun 2, 2026 | Maduck Sean | See Remarks | F | 452 | $70.44 | $31.8K |
| Jun 2, 2026 | Mokari Atabak | Chief Financial Officer | F | 395 | $70.44 | $27.8K |
| Jun 2, 2026 | Robb Gary Charles | Chief Business Officer | F | 358 | $70.44 | $25.2K |
| Jun 1, 2026 | Lyon Joseph Douglas | See Remarks | A | 537 | $70.44 | $37.8K |
| Jun 1, 2026 | Guyer William | Chief Development Officer | A | 877 | $70.44 | $61.8K |
| Jun 1, 2026 | Maduck Sean | See Remarks | M | 25,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Maduck Sean | See Remarks | A | 615 | $70.44 | $43.3K |
| Jun 1, 2026 | Maduck Sean | See Remarks | SELL | 21,069 | $70.11 | $1.5M |
| Jun 1, 2026 | Maduck Sean | See Remarks | M | 25,000 | $8.27 | $206.8K |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | M | 40,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | A | 634 | $70.44 | $44.7K |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | SELL | 40,000 | $70.00 | $2.8M |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | M | 40,000 | $19.26 | $770.4K |
| Jun 1, 2026 | Robb Gary Charles | Chief Business Officer | A | 776 | $70.44 | $54.7K |
| Jun 1, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | SELL | 12,837 | $69.74 | $895.3K |
| May 29, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | G | 300,000 | $0.00 | $0.00 |
| May 27, 2026 | WILSON JAMES N | Director | G | 892,056 | $0.00 | $0.00 |
| May 27, 2026 | Maduck Sean | See Remarks | M | 75,000 | $8.27 | $620.3K |
| May 27, 2026 | Maduck Sean | See Remarks | SELL | 54,575 | $65.37 | $3.6M |
| May 27, 2026 | Maduck Sean | See Remarks | M | 75,000 | $0.00 | $0.00 |
| May 27, 2026 | Lyon Joseph Douglas | See Remarks | SELL | 5,000 | $65.00 | $325.0K |
| May 21, 2026 | Park Kimberly | Director | A | 12,500 | $0.00 | $0.00 |
| May 21, 2026 | MAHONEY DAVID L | Director | A | 12,500 | $0.00 | $0.00 |
| May 21, 2026 | Murray Joshua M. | Director | A | 12,500 | $0.00 | $0.00 |
| May 21, 2026 | Swisher Daniel N JR | Director | A | 12,500 | $0.00 | $0.00 |
| May 21, 2026 | WILSON JAMES N | Director | A | 12,500 | $0.00 | $0.00 |
| May 21, 2026 | BAKER G LEONARD JR | Director | A | 12,500 | $0.00 | $0.00 |
| May 21, 2026 | Alton Gregg H | Director | A | 12,500 | $0.00 | $0.00 |
| May 13, 2026 | Robb Gary Charles | Chief Business Officer | G | 5,300 | $0.00 | $0.00 |
| May 5, 2026 | Guyer William | Chief Development Officer | M | 20,000 | $0.00 | $0.00 |
| May 5, 2026 | Guyer William | Chief Development Officer | SELL | 20,000 | $51.83 | $1.0M |
| May 5, 2026 | Guyer William | Chief Development Officer | M | 20,000 | $21.65 | $433.0K |
| May 1, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | SELL | 40,000 | $50.10 | $2.0M |
| Apr 22, 2026 | WILSON JAMES N | Director | G | 2,000 | $0.00 | $0.00 |
| Apr 7, 2026 | Guyer William | Chief Development Officer | M | 20,000 | $21.65 | $433.0K |
| Apr 7, 2026 | Guyer William | Chief Development Officer | SELL | 20,000 | $40.97 | $819.4K |
| Apr 7, 2026 | Guyer William | Chief Development Officer | M | 20,000 | $0.00 | $0.00 |
| Apr 6, 2026 | WILSON JAMES N | Director | G | 5,000 | $0.00 | $0.00 |
| Mar 25, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | SELL | 26,198 | $50.07 | $1.3M |
| Mar 20, 2026 | WILSON JAMES N | Director | G | 4,000 | $0.00 | $0.00 |
| Mar 20, 2026 | Guyer William | Chief Development Officer | M | 11,767 | $21.65 | $254.8K |
| Mar 20, 2026 | Guyer William | Chief Development Officer | SELL | 11,767 | $36.01 | $423.7K |
| Mar 20, 2026 | Guyer William | Chief Development Officer | M | 11,767 | $0.00 | $0.00 |
| Mar 17, 2026 | BAKER G LEONARD JR | Director | BUY | 75,782 | $33.00 | $2.5M |
| Mar 13, 2026 | MAHONEY DAVID L | Director | M | 30,000 | $5.86 | $175.8K |
| Mar 13, 2026 | MAHONEY DAVID L | Director | F | 5,469 | $32.15 | $175.8K |
12 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 9 neutral. Avg impact: 3.9/10.
NEUTRAL
CLUSTER
3/10
Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a to
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Four CORT insiders — including the CEO, CFO, and two senior executives — sold a total of $5.50M in o
Jun 3, 2026
BEARISH
CLUSTER
5/10
Four Corcept Therapeutics insiders, including the CEO, CFO, and two other senior executives, sold a
Jun 3, 2026
NEUTRAL
CLUSTER
4/10
Three top executives at Corcept Therapeutics (CEO, CFO, and a senior officer) sold a total of $7.59M
Jun 3, 2026
NEUTRAL
CLUSTER
3/10
CEO Joseph Belanoff sold $895K worth of CORT shares on June 1, and two other executives sold a combi
Jun 3, 2026
BULLISH
8-K
6/10
Corcept disclosed that the DOJ, California Department of Insurance, and named Plaintiff States have
Jun 3, 2026
NEUTRAL
CLUSTER
3/10
Two Corcept Therapeutics insiders sold a combined $3.89M in open-market sales on May 27, 2026, with
Jun 2, 2026
NEUTRAL
CLUSTER
3/10
Two Corcept Therapeutics insiders sold a total of ~$3.9M in open-market shares on May 27, 2026, whil
May 29, 2026
NEUTRAL
CLUSTER
3/10
Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings
May 7, 2026
NEUTRAL
CLUSTER
3/10
Corcept Therapeutics CEO Joseph Belanoff sold $1.31M worth of shares in a single open-market transac
Mar 27, 2026
NEUTRAL
CLUSTER
4/10
Chief Development Officer William Guyer exercised stock options and sold 11,767 shares in the open m
Mar 24, 2026
BULLISH
8-K
7/10
Corcept Therapeutics reported full-year 2025 revenue of $761.4 million, a 12.8% increase from 2024,
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 2 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$88.00 mean target
+21.2% upside
Strong Buy (1.50)
$50.00 Low
$135.00 High
| Metric | Value |
|---|---|
| Current Price | $72.62 |
| Target Low | $50.00 |
| Target Mean | $88.00 |
| Target Median | $88.00 |
| Target High | $135.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.04 | $0.02 | $0.06 | -87.4% | -29.5% | 1↑ 2↓ | $0.2B | 14.3% | 3 |
| Next Q 2026-09-30 |
$0.25 | $0.14 | $0.34 | 58.3% | +56.4% | 2↑ 1↓ | $0.3B | 28.4% | 3 |
| Current FY 2026-12-31 |
$0.49 | $0.17 | $0.80 | -40.6% | +20.1% | 2↑ 1↓ | $1.0B | 29.8% | 4 |
| Next FY 2027-12-31 |
$2.50 | $0.32 | $5.38 | 411.8% | +55.2% | 2↑ 1↓ | $1.4B | 41.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.037 | |
| 7d ago | $0.037 | |
| 30d ago | $0.052 | -0.015 |
| 60d ago | $0.052 | -0.015 |
| 90d ago | $0.028 | +0.009 |
5 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 13, 2026 | UBS | UPGRADE | Neutral | Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 1, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 26, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Wolfe Research | UPGRADE | Underperform | Peer Perform |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | UBS | INITIATE | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 7 | 2 | 0 | 1 | 75% | |
| Feb 1, 2026 | 2 | 7 | 2 | 0 | 1 | 75% | |
| Jan 1, 2026 | 2 | 7 | 2 | 0 | 1 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
CASE STUDY CORT
▲ 1
💬 0
⚡ 0.5
Jul 11, 2026
fda_pdufa
PDUFA: CORT — relacorilant in platinum-resistant ovarian cancer — 2026-07-11
FDA target action date 2026-07-11 for CORT (CORCEPT THERAPEUTICS INC). Drug: relacorilant. Indication: platinum-resistant ovarian cancer. PDUFA target
Jun 3, 2026
Clinical Trial
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Miricorilant (Cohort A) (Phase 2)
Trial: A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis
May 27, 2026
short_volume
Short Volume: CORT — 74.7% short (0.6M / 0.8M)
Short: 570,622 | Exempt: 11,128 | TRF Vol: 764,205 | Short Ratio: 74.7% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CORT — 86.6% short (0.5M / 0.6M)
Short: 534,051 | Exempt: 3,237 | TRF Vol: 616,568 | Short Ratio: 86.6% | Off-exchange volume (dark pool + OTC)
May 16, 2026
Clinical Trial
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase Phase 2 — TERMINATED
May 14, 2026
short_volume
Short Volume: CORT — 83.5% short (0.6M / 0.7M)
Short: 562,804 | Exempt: 1,826 | TRF Vol: 673,707 | Short Ratio: 83.5% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: CORT — 2.1M shares, 40,445 trades
Week starting 2026-05-11. Total ATS volume: 2,053,057 shares across 40,445 trades.
May 4, 2026
dark_pool
Dark Pool: CORT — 1.4M shares, 31,628 trades
Week starting 2026-05-04. Total ATS volume: 1,427,344 shares across 31,628 trades.
May 1, 2026
short_volume
Short Volume: CORT — 71.7% short (0.8M / 1.2M)
Short: 842,516 | Exempt: 100 | TRF Vol: 1,174,740 | Short Ratio: 71.7% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_interest
FTD: CORT — 99,904 shares ($4.6M) failed to deliver
Settlement: 20260501, Price: $46.52, FTD Value: $4,647,534.08, CORCEPT THERAPEUTICS INCORPORA
Apr 30, 2026
earnings_calendar
CORT Q1 2026 Earnings Scheduled — 2026-04-30
Apr 27, 2026
dark_pool
Dark Pool: CORT — 2.1M shares, 51,005 trades
Week starting 2026-04-27. Total ATS volume: 2,116,844 shares across 51,005 trades.
Apr 20, 2026
dark_pool
Dark Pool: CORT — 1.2M shares, 25,017 trades
Week starting 2026-04-20. Total ATS volume: 1,198,432 shares across 25,017 trades.
Apr 13, 2026
dark_pool
Dark Pool: CORT — 1.3M shares, 29,147 trades
Week starting 2026-04-13. Total ATS volume: 1,289,082 shares across 29,147 trades.
Apr 6, 2026
short_interest
FTD: CORT — 53,237 shares ($2.3M) failed to deliver
Settlement: 20260406, Price: $42.49, FTD Value: $2,262,040.13, CORCEPT THERAPEUTICS INCORPORA
Apr 6, 2026
dark_pool
Dark Pool: CORT — 1.4M shares, 28,056 trades
Week starting 2026-04-06. Total ATS volume: 1,414,990 shares across 28,056 trades.
Mar 25, 2026
FDA
LIFYORLITM
Original Approval — Type 1 - New Molecular Entity — RELACORILANT — CAPSULE — ORAL
Feb 23, 2026
Clinical Trial
A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas
Phase Phase 2 — TERMINATED